Vedolizumab
Based on 3 publication(s) in Google Scholar
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.90%
- CAS 番号: 943609-66-3
- 分子量:146.868 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-108831
NatalizumabAnti-α4 Integrin Monoclonal Antibody -
HY-P9984
Etrolizumabβ7 Integrin Inhibitor -
HY-P9970
InfliximabTNF-α Inhibitor -
HY-P9909
Ustekinumab -
HY-P99184
AbrilumabAnti-Human α4β7 -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-108831A
Natalizumab (Anti-CD49d)Anti-α4 Integrin Monoclonal Antibody -
HY-P9931
GuselkumabIL-23 Neutralizing Antibody -
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P99737
MirikizumabIL-23 Antibody -
HY-P9911A
Vedolizumab (anti-α4β7-integrin)
MedChemExpress（MCE）の使用を引用している文献 Vedolizumab
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
ELISA
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
生物活性
製品説明
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Integrin a4b7
体外実験
Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06 μg/mL) and fibronectin (IC50=0.02 μg/mL), but not vascular cell adhesion molecule 1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 Jurkat cells with Vedolizumab (HY-P9911, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Immobilized Human Integrin alpha 4 beta 7 Protein (His Tag) can bind Vedolizumab. The EC50 for this effect is 119.52 ng/mL.
化学情報
-
CAS 番号 943609-66-3
-
性状 Liquid
-
分子量 146.868 kDa
-
Color Colorless to light yellow
-
SMILES
[Vedolizumab]
-
別名
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease. [Abstract]2025 Jan;37(4):e2412429. PMID: 39641224
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days) decreased MPO levels in DSS-treated mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) effectively repaired pathological damage in the colonic tissues of IBD mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]
Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) significantly decreased colonic TNF-α, IL-6, and IL-1β levels in IBD mice.
-
Brain Behav Immun
Pro-inflammatory macrophages contribute to developing comorbid anxiety-like behaviors through gastrointestinal vagal afferent signaling in experimental colitis mice. [Abstract]2025 May 8:128:620-633. PMID: 40348137
Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]
Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced the disease activity index of DSS-induced colitis mice.
Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]
Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced histological damage of colon tissues of DSS-induced colitis mice.
-
Anal Chim Acta
Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]2021 Apr 15:1154:338306. PMID: 33736796
プロトコル
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
純度とドキュメンテーション
-
データシート (263 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [Content Brief]
[2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Vedolizumab 関連分類
HY-P9911 関連分類
Powered by Bioz